drugset / Trial / NCT00014144
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.
Timeline
- Start
- 2001-02
- Primary completion
- 2003-05
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |